Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized active-controlled study of budesonide + formoterol inhalation powder in asthma
CTR20253771Phase 3Active
- Sponsor
- Resplip Pharmaceutical
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide, formoterol in asthma, sponsored by Resplip Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20253771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253771.